CTRI/2020/10/028220RecruitingPhase 2
A phase II randomized study to evaluate the efficacy of short-course RR CVEP regimen against short course EPOCH-RR in adolescent and adult seropositive Diffuse large B cell lymphoma.
Tata Memorial Hospital Research Administrative Council0 sites0 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1. Patients with histologically proven AIDS related diffuse large B cell lymphoma (excluding Burkittââ?¬•s or Burkittââ?¬•s-like lymphomas) with or without CNS involvement
- •2. No prior chemotherapy for lymphoma
- •3. Absolute CD4 count >50/Ã?µL.
- •4. Age- 15-65 years
- •5. ECOG Performance status <4
- •6. Adequate organ function
- •7. Written informed consent
- •8. Able to comply with the study protocol- absence of psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
Exclusion Criteria
- •1.Presence of other co-morbidities (e.g. uncontrolled diabetes mellitus, uncontrolled hypertension, cerebrovascular event in last 6 months, myocardial infarction within last 6 months, uncontrolled arrhythmias, congestive heart failure, other conditions) which can result in poor tolerance to therapy in investigators opinion.
- •2. Ongoing uncontrolled infections
- •3. Primary CNS lymphoma
- •4. Pregnancy
- •5. Patients on anti-tubercular therapy or other enzyme inducer drugs.
Investigators
Similar Trials
Recruiting
Phase 2
A study on the efficacy and safety of cisplatin/etoposide and concomitant radiotherapy in combination with durvalumab, an immunotherapy, in patients with local limited small cell lung cancer2024-513433-20-00Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR105
Active, not recruiting
Phase 1
A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs)Salivary gland cancerMedDRA version: 17.0Level: PTClassification code 10061934Term: Salivary gland cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000314-38-FREuropean Organisation for Research and Treatment of Cancer (EORTC)452
Active, not recruiting
Phase 1
A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs)Salivary gland cancerMedDRA version: 20.0Level: PTClassification code 10061934Term: Salivary gland cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000314-38-BEEuropean Organisation for Research and Treatment of Cancer (EORTC)220
Active, not recruiting
Phase 1
A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs)EUCTR2013-000314-38-NLEuropean Organisation for Research and Treatment of Cancer (EORTC)220
Recruiting
Phase 2
A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs)salivary duct carcinoma10072990NL-OMON54823European Organisation for Research in Treatment of Cancer (EORTC)1